An update on autoinflammatory diseases. new concepts for new and old diseases

Clinical and Experimental Rheumatology

Volumn 27, Issue 2, 2009, Pages 354-365

  Gattorno, M ^a,c   Regina, M La ^b   Martini, A ^a   Manna, R ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Autoinflammatory diseases; Familial Mediterranean fever; Innate immunity; Periodic fever

Indexed keywords

ACETYLSALICYLIC ACID; ACZ 885; ALPHA INTERFERON; AMYLOID A PROTEIN; ATLIZUMAB; CASPASE RECRUITMENT DOMAIN PROTEIN 15; COLCHICINE; CORTICOSTEROID; CRYOPYRIN; EPRODISATE; ETANERCEPT; IMMUNOGLOBULIN D; INFLIXIMAB; MEVALONATE KINASE; MONOCLONAL ANTIBODY; PAMIDRONIC ACID; PHOSPHATASE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; SIMVASTATIN; STEROID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ABSCESS; AMYLOIDOSIS; ANTIBIOTIC THERAPY; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; BLAU SYNDROME; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CINCA SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FEVER; FIBROUS DYSPLASIA; GENE; GENE MUTATION; GOUT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; MAJEED SYNDROME; MEFV GENE; MEVALONATE KINASE DEFICIENCY; MONOTHERAPY; MUCKLE WELLS SYNDROME; MULTIPLE CYCLE TREATMENT; MYALGIA; NONHUMAN; OSTEOMYELITIS; PAPA SYNDROME; PATHOGENESIS; PERICARDITIS; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RECURRENT FEVER; SARCOIDOSIS; SINGLE DRUG DOSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTI-INFLAMMATORY AGENTS; APOPTOSIS REGULATORY PROTEINS; AUTOIMMUNE DISEASES; CYTOSKELETAL PROTEINS; FEVER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; SYNDROME;

EID: 67449086212     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (97)

1. MCGONAGLE D. MCDERMOTT MF: A proposed classification of the immunological diseases. Plos Medicine 2006; 3: 1242-8.
2. CHITKARA P, STOJANOV S. KASTNER DL: The hereditary autoinflammatory syndromes. Pediatr Infect Dis J 2007; 26: 353-4.
3. JAIN V. HALLE A, HALMEN KA et al.: Phagocytosis and intracellular killing of MD-2 opsonized Gram-negative bacteria depend on TLR4signaling.fi/ ood2008; 111:4637-45.
4. BIANCHI ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1-5.
5. PALUMBO R. GALVEZ BG, PUSTERLA T et al: Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappa B activation. J Cell Biol 2007; 179: 33-40.
6. RUBARTELLI A, COZZOLINO F. TALIO M, SITIA R: A novel secretory pathway for in-terleukin-1 beta, a protein lacking a signal sequence. EMBO J 1990; 9: 1503-10.
7. ANDREI C, DAZZI C, LOTTI L, TORRISI MR. CHIMINI G, RUBARTELLI A: The secretory route of the leaderless protein interleukin lbeta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell 1999; 10: 1463-75.
8. SOLLE M. LABASI J, PERREGAUX DG et al.: Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 2001; 276: 125-32.
9. PICCIN1 A. CARTA S, TASS1 S, LASIGL1E D, FOSSATI G. RUBARTELLI A: ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1 beta and IL-18 secretion in an autocrine way. Proc Nat Acad Sci USA 2008; 105: 8067-72.
10. FERRARI D, PIZZIRANI C, ADINOLFI E et al: The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006; 176: 3877-83.
11. GATTORNO M, TASSI S, CARTA S et al: Pattern of interleukin-lbeta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007; 56: 3138-48.
12. MARTINON F, PETRILLI V, MAYOR A, TARDI-VEL A, TSCHOPP J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
13. SO A. DE SMEDT T, REVAZ S. TSCHOPP J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.
14. MCGONAGLE D, TAN AL, SHANKARANA-RAYANA S, MADDEN J, EMERY P, MCDERMOTT MF: Management of treatment resistant inflammation of acute on chronic topha-ceous gout with anakinra. Ann Rheum Dis 2007; 66: 1683-4.
15. CASSEL SL, EISENBARTH SC. IYER SS et al: The Nalp3 inflammasome is essential for the development of silicosis. Proc Nat Acad Sci USA 2008; 105: 9035-40.
16. EISENBARTH SC, COLEGIO OR, O'CONNOR W, SUTTERWALA FS, FLAVELL RA: Crucial role for the Nalp3 inflammasome in the im-munostimulatory properties of aluminium adjuvants. Nature 2008; 453: 1122-U13.
17. BUFLER P, GAMBONI-ROBERTSON F. AZAM T, KIM SH, DINARELLO CA: Interleukin-1 homologues lL-lF7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J 2004; 381: 503-10.
18. JIN Y, BIRLEA SA, FAIN PR, SPRITZ RA: Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 2007; 127: 2558-62.
19. ROSENGREN S, HOFFMAN HM. BUGBEE W, BOYLE DL: Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis 2005; 64: 708-14.
20. TSCHOPP J, MARTINON F, BURNS K: NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003; 4: 95-104.
21. HOFFMAN HM, MUELLER JL. BROIDE DH, WANDERER AA, KOLODNER RD: Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 200\; 29: 301-5.
22. GOLDBACH-MANSKY R, DAILEY NJ. CAN-NA SW et al: Neonatal-onset multisystem inflammatory disease responsive to interleukin-lbeta inhibition. N Engl J Med 2006; 355:581-92.
23. HOFFMAN HM, THRONE ML, AMAR NJ et al: Efficacy and safety of rilonacept (interleukin- 1 Trap) in patients with cryopyrin-as-sociated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443-52.
24. GOLDBACH-MANSKY R, SHROFF SD, WILSON M et al.: A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (Interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58: 2432-42.
25. BALOW J, SUN H, GODBACH-MANSKY R, KASTNER D, AKSENTIJEVICH I: Microarray-based gene expression studies of systemic inflammation in patients with cryopyrin-as-sociated periodic syndromes (CAPS). Clin Exp Rheumatol 2008; 26: 178 (Abstract).
26. BRYDGES S, MUELLER J. MISAGHI A et al: Initial characterization of a mouse model of cryopyrinopathy. Clin Exp Rheumatol 2008; 26: 179 (Abstract).
27. MURDOCH S, DJURIC U, MAZHAR B et al: Mutations in NALP7 cause recurrent hyda-tidiform moles and reproductive wastage in humans. Nat Genet 2006; 38: 300-2.
28. SLIM R, MEHIO A: The genetics of hydatidi-form moles: new lights on an ancient disease. Clin Genet 2001; 71: 25-34.
29. JERU I, DUQUESNOY P, FERNANDES-AL-NEMRI T et al: Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA200%\ 105: 1614-9.
30. LICH JD, TING JP: Monarch-1/PYPAF7 and other CATERPILLER (CLR, NOD, NLR) proteins with negative regulatory functions. Microbes Infect 2007; 9: 672-6.
31. CHAE JJ, WOOD G, MASTERS SL et al: The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1 beta production. Proc Natl Acad Sci USA 2006; 103: 9982-7.
32. CHAE JJ, KOMAROW HD. CHENG J et al: Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endo-toxin and a defect in macrophage apoptosis. Mol Cell 2003; 11:591-604.
33. SAMUELS J, AKSENTIJEVICH I, TOROSYAN Y et al: Familial Mediterranean fevet al the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77: 268-97.
34. OZEN S, AKTAY N, LAINKA E, DUZOVA A, BAKKALOGLU A. KALLINICH T: Disease severity in children and adolescents with Familial Mediterranean Fever: A comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis 2008.
35. STOJANOV S, CHAE J, WOOD G et al: Altered development and function of CD1 lc+cells in pyrin-null mice. Clin Exp Rheumatol 2008; 26: 177 (Abstract).
36. WOOD G, BALOW J, SUN H, SHOHAM N, KASTNER D: RNA interference of MEFV in THP. 1 cells reveals a role for endogenous pyrin in Toll-like receptor signaling (TLR) that is mediated by the transcription factor IRF2. Clin Exp Rheumatol 2008; 26: 178 (Abstract).
37. KALLINICH T, WITTKOWSKI H, KEITZER R, ROTH J, FOELL D: S-100A12 as a sensitive marker for the detection of inflammation in children and adolescents with Familial Mediterranean Fever. Clin Exp Rheumatol 2008; 26: 176-7 (Abstract).
38. LA REGINA M, LIVNEH A. MANNA R, OZ-DOGAN H: Trends in colchicine treatment in Familial Mediterranean fever (FMF). Clin Exp Rheumatol 2008; 26: 177 (Abstract).
39. YALCINKAYA F, OZEN S, OZCAKAR Z et al.: A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Clin Exp Rheumatol 2008; 26: 178.
40. VERRECCHIA E, CURIGLIANO V, MONTALTO M et al.: Role of small intestinal bacterial overgrowth in colchicine non-responders. Clin Exp Rheumatol 2008; 26: 177 (Abstract).
41. VAN DER MEER JW, VOSSEN JM. RADLJ et al: Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984; 1: 1087-90.
42. HOUTEN SM. KUIS W. DURAN M et al: Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nature Genetics 1999; 22: 175-7.
43. AMMOURI W. CUISSET L, ROUAGHE S et al: Diagnostic value of serum immunoglob-ulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford) 2007; 46: 1597-600.
44. KUIJK LM, BEEKMAN JM, KOSTER J, WATERHAM HR. FRENKEL J, COFFER PJ: HMG-CoA reductase inhibition induces IL-l{beta} release through Racl/PI3K7PKB-dependent caspase-1 activation. Blood 2008; 112: 3563-73.
45. VAN DER H1LST JC, BODAR EJ, BARRON KS et al: Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008; 87: 301-10.
46. GATTORNO M, SORMANI MR D'OSUALDO A et al:. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 58: 1823-32.
47. WILLIAMSON LM, HULL D, MEHTA R. REEVES WG, ROBINSON BH. TOGHILL PJ: Familial Hibernian fever. Q J Med 1982; 51: 469-80.
48. MCDERMOTT MF, AKSENTIJEVICH I. GALON J et al.: Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-44.
49. HUGG1NS ML. RADFORD PM. MclNTOSH RS et al.: Shedding of mutant tumour necrosis factor receptor superfamily 1A associated with tumour necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum 2004; 50: 2651-9.
50. SIEBERT S, FIELDING CA, WILLIAMS BD. BRENNAN P: Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF-kappaB activation due to decreased surface expression. FEBS Lett 2005; 579: 5193-8.
51. TODD I. RADFORD PM, DRAPER-MORGAN KA et al.: Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 2004; 113: 65-79.
52. REBELO SL. BAINBRIDGE SE, MEL-KASHI-PAZ MR et al.: Modeling of tumour necrosis factor receptor superfamily 1A mutants associated with tumour necrosis factor receptor-associated periodic syndrome indicates mis-folding consistent with abnormal function. Arthritis Rheum 2006; 54: 2674-87.
53. LOBITO AA, KIMBERLEY FC, MUPPIDI JR et al.: Abnormal disulfide-linked oligomeri-zation results in ER retention and altered signaling by TNFR1 mutants in TNFR 1-associated periodic fever syndrome (TRAPS). Blood 2006: 108: 1320-7.
54. TODD I, RADFORD PM, DAFFA N, BAINBRIDGE SE, POWELL RJ, TIGHE PJ: Mutant tumour necrosis factor receptor associated with tumour necrosis factor receptor-associated periodic syndrome is altered antigeni-cally and is retained within patients' leukocytes. Arthritis Rheum 2007; 56: 2765-73.
55. D'OSUALDO A. FERLITO F, PR1G1ONE I et al.: Neutrophils from patients with TNFRSF1A mutations display resistance to tumour necrosis factor-induced apoptosis - Patho-genetic and clinical implications. Arthritis Rheum 2006; 54: 998-1008.
56. GATTORNO M. PELAGATTI MA. MEINI A et al.: Persistent efficacy of anakinra in patients with tumour necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516-20.
57. NEDJAI B, HITMAN GA. YOUSAF N et al.: Abnormal tumour necrosis factor receptor I cell surface expression and NF-kappaB activation in tumour necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 273-83.
58. RYAN J. BALOW JJ, BARHAM B. BARRON K, KASTNER D. AKSENTIJEVICH I: Identification and analysis of gene-expression signatures in peripheral blood leukocytes of patients with TRAPS. Clin Exp Rheumatol 2008; 26: 182.
59. M1CELI-R1CHARD C, LESAGE S. RYBOJAD M etal: CARD 15 mutations in Blau syndrome. Nat Genet 2001; 29: 19-20.
60. BLAU EB: Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985: 107: 689-93.
61. ROSE CD. WOUTERS CH, MEIORIN S et al.: Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006; 54: 3337-44.
62. WOUTERS CH. MARTIN TM, STICHWEH D et al.: Infantile onset panniculitis with uveitis and systemic granulomatosis: a new clinico-pathologic entity. J Pediatr 2007; 151: 707-9.
63. WISE CA, GILLUM JD, SEIDMAN CE et al.: Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002; 11:961-9.
64. LINDOR NM, ARSENAULT TM. SOLOMON H. SEIDMAN CE. MCEVOY MT: A new auto-somal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum. and acne: PAPA syndrome. Mayo Clin Proc 1997: 72: 611-5.
65. SHOHAM NG, CENTOLA M, MANSFIELD E et al:. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003; 100: 13501-6.
66. YU JW, FERNANDES-ALNEMRI T, DATTA P et al:. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 2007: 28: 214-27.
67. YU JW, WU J, ZHANG Z et al:. Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ 2006; 13: 236-49.
68. MAJEED HA, KALAAWI M. MOHANTY D et al: Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. J Pedi-afr 1989; 115 (Pt 1): 730-4.
69. FERGUSON PJ. CHEN S. TAYEH MK et al: Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 2005; 42: 551 -7.
70. FERGUSON PJ. BING X. VASEF MA et al:. A missense mutation in pstpip2 is associated with the murine autoinflammatory disorder chronic multifocal osteomyelitis. Bone 2006: 38:41-7.
71. MARSHALL GS. EDWARDS KM. BUTLER J. LAWTON AR: Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr 1987; 110:43-6.
72. RAVELLI A. MARTINI A: Juvenile idiopathic arthritis. Lancet 2007: 369: 767-78.
73. DE BENEDETTI F. MARTINI A: Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998: 25: 203-7.
74. PASCUAL V. ALLANTAZ F. ARCE E. PUNARO M. BANCHEREAU J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005: 201: 1479-86.
75. YOKOTA S. 1MAGAWA T. MORI M et al: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008:371:998-1006.
76. GATTORNO M. PICCIM A. LAS1GLIE D el al: The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 1505-15.
77. DE KONING HD. BODAR EJ. VAN DER MEER JW. SIMON A: Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137-48.
78. RAMADAN KM. ESWED1 HA. El.-AGNAF MR: Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab. Br J Dermatol 2007; 156: 1072-4.
79. BRUCATO A. BRAMBILLA G. ADLER Y. SPODICK DH: Recurrent pericarditis: therapy of refractory cases. Eur Heart J 2005: 26: 2600-1.
80. IMAZIO M. BRUCATO A. TRINCHERO R. SHABETAI R. SPODICK D. ADLER Y: Corti-costeroid therapy for pericarditis: a double-edged sword. Nat Clin Pract Canliovasc Med 2008: 5: 118-9.
81. PICCO P. BRISCA G. TRAVERSO F. LOY A. GATTORNO M. MARTINI A: Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1 beta receptor antagonist (anakinra): An unrecognized autoinflammatory disease? Arthritis Rheum 2009: 60: 264-8.
82. ANDRE MF. P1ETTE JC. KEMENY JL et al: Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore) 2007; 86: 145-61.
83. ROSEN-WOLFF A, ROMANOWSKI M, FLECKS S et al: Mutated, structurally altered caspase-1 with decreased enzymatic and increased RIP2 mediated inflammatory activity leads to a new type of periodic fever (ICE fever). Clin Exp Rheumatol 2008; 26: 175.
84. UEK1 Y, TIZIAN1 V, SANTANNA C et al: Mutations in the gene encoding c-Abl-bind-ing protein SH3BP2 cause cherubism. Nat Genet 2001; 28: 125-6.
85. FERGUSON P, AZAR A, EL-SHANT1 H, BING XI, BALLAS Z: A mutation in exon 8 of the cherubism Gene is associated with a novel autointlammatory phenotype that affects the skin and the bone. Clin Exp Rheumatol 2008; 26: 173 (Abstract).
86. KITANO Y, MATSUNAGA E, MORIMOTO T, OKADA N, SANO S: A syndrome with nodular erythema, elongated and thickened fingers, and emaciation. Arch Dermatol 1985; 121: 1053-6.
87. KANAZAWA N. MIKITA N, FURUKAWA F et al.: Familial Japanese fever (Nakajo-Nishimura syndrome): a novel hereditary periodic fever with partial lipodystrophy and a search for LPIN gene mutations. Clin Exp Rheumatol 2008; 26: 174 (Abstract).
88. LACHMANN HJ, GOODMAN HJ, GILBERT-SON JA et al.: Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-71.
89. DEMBER LM, HAWKINS PN, HAZENBERG BP et al.: Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356: 2349-60.
90. HATEMI G, TASCILAR K, YURDAKUL S. OZDOGAN H: Tumour necrosis factor alpha antagonists in the treatment of secondary amyloidosis. Clin Exp Rheumatol 2008; 26: 173 (Abstract).
91. BALCI-PEYNIRCIOGLU B, WA1TE A, SCHAN-ER P et al.: Expression of ASC in renal tissues of IMF patients with amyloidosis; postulating a role for ASC in AA type amyloid deposition. Clin Exp Rheumatol 2008; 26: 173 (Abstract).
92. HAWKINS PN, LACHMANN HJ, McDERMOTT MF: Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. A' Engl J Med 2003; 348: 2583-4.
93. FITZGERALD AA, LECLERCQ SA, YAN A, HOMIK JE, DINARELLO CA: Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005; 52: 1794-803.
94. RADIN A, TERKELTAUB R, SCHUMACHER H et al.: Placebo-controlled pilot study of rilonacept (IL-1 Trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Clin Exp Rheumatol 2008; 26: 181 (Abstract).
95. KUEMMERLE-DESCHNERJB.TZARIBACHEV N, HAUSMANN S et al: Long-lasting response to ACZ885 (a new human IgGl anti-IL-1 beta monoclonal antibody) in patients with Muckle-Wells Syndrome (MWS). Clin Exp Rheumatol 2008; 26: 180 (Abstract).
96. LACHMANN H, JUNG T, FELIX Set al: Treatment of cryopyrin associated periodic fever syndrome with a fully human anti-IL-1 beta monoclonal antibody (ACZ885): results from a subcutaneous administration study. Clin Exp Rheumatol 2008; 26: 181 (Abstract).
97. MIETTUNEN P, WEI C, KAURA D, ABOU RW, NETTEL AA, KELLNER J: Effective treatment with IV pamidronate in chronic recurrent multifocal osteomyelitis (CRMO)-resolu-tion of pain, normalization of radiologic abnormalities, and improvement of elevated urine-N-telopept. Clin Exp Rheumatol 2008; 26:181 (Abstract).